文献速递免疫规划卫生政策与健康促进

澳大利亚孕产妇呼吸道合胞病毒(RSV)疫苗接种的成本效果估算:动态与经济模型分析

Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
PubMed 文献 · Vaccine · 2024-12-28

研究运用动态与经济评价整合模型,估算澳大利亚全年孕产妇RSV疫苗接种项目的成本效果。医疗系统视角下,疫苗价格低于约120澳元时具成本效果(支付意愿阈值50,000澳元/QALY)。82%的成本节约来自预防<6月龄婴儿住院,但仅约25%的QALY增益在该年龄组;排除≥6月龄的成本节约与QALY增益后,满足阈值的疫苗价格降至63澳元。

要点

  • 全年孕产妇RSV疫苗接种项目在疫苗价格低于约120澳元时具成本效果。
  • 82%成本节约来自预防<6月龄婴儿RSV住院,但该年龄组仅占约25%的QALY增益。
  • 多数其他QALY增益来自 herd effects(群体效应),即预防老年人死亡及减少较大青少年和成人非就医疾病。

核心结论

  • 澳大利亚孕产妇RSV疫苗接种项目可通过减少<6月龄婴儿住院及相关费用提供经济价值,具体取决于疫苗价格。
  • 目标人群之外的 herd effects(群体效应)可能是评估孕产妇RSV疫苗接种成本效果的重要考虑因素。

研究设计与样本

  • 研究应用整合动态与经济评价模型,估算澳大利亚全年孕产妇RSV疫苗接种项目的特定结局与成本效果。
  • 成本效果以每获得一个质量调整生命年(QALY)的增量成本效果比(ICER)估算。

主要发现

  • 医疗系统视角下,假设支付意愿阈值为50,000澳元/QALY,疫苗价格低于约120澳元时项目具成本效果。
  • 82%的成本节约来自预防<6月龄婴儿RSV住院,但仅约25%的QALY增益在该年龄组。
  • 多数其他QALY增益来自 herd effects(群体效应),即预防老年人死亡,以及较小程度来自预防较大青少年和成人非就医疾病。
  • 排除≥6月龄的成本节约与QALY增益后,满足假设支付意愿阈值所需疫苗价格降至63澳元。

关键数值与推荐

  • 支付意愿阈值假设为50,000澳元/QALY。
  • 医疗系统视角下,疫苗价格低于约120澳元时项目具成本效果。
  • 排除≥6月龄的成本节约与QALY增益后,满足支付意愿阈值所需疫苗价格降至63澳元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory illness, with younger infants at greatest risk of hospitalisation. With the recent approval of a maternal RSV vaccine in Australia, it is timely to evaluate its potential costs and health benefits in Australia. METHODS: We applied an integrated dynamic and economic evaluation model to estimate specific outcomes of RSV disease and the cost-effectiveness of a year-round maternal RSV vaccination program in Australia. Cost-effectiveness was estimated using the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained. RESULTS: From a healthcare system perspective, the maternal vaccination program was estimated to be cost-effective at a vaccine price less than approximately 120 Australian dollars ($AU), assuming a willingness-to-pay (WTP) threshold of $AU 50,000/QALY gained. Most of the estimated cost-savings were from preventing RSV hospitalisations in infants aged <6 months. However, while 82% of the cost-savings were from preventing RSV hospitalisations in infants aged <6 months, only about 25% of the QALY gains were in this age group. The majority of the other QALY gains came via herd effects from prevention of death in older adults and to a lesser extent, prevention of nonmedically-attended illness in older teens and adults. When predicted cost-savings and QALY gains in those ≥6 months of age were excluded, the vaccine price required to meet the assumed WTP threshold fell to $AU 63. CONCLUSIONS: A maternal RSV vaccination program in Australia could provide value for money by reducing hospitalisations and associated costs among infants aged <6 months, depending on the vaccine price. We have provided evidence that herd effects beyond the target population may be an important consideration in assessing cost-effectiveness of maternal RSV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nazareno AL, Wood JG, Muscatello DJ, et al. Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis. Vaccine. 2024. PMID: 39733477. doi:10.1016/j.vaccine.2024.126651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。